– USA, IL – Sagent Pharmaceuticals, Inc. (Nasdaq:SGNT), a leader of specialty pharmaceutical products with an emphasis on the injectable market, today announced that Shlomo Yanai has been appointed to its Board of Directors effective April 15, 2015.
“We are delighted to have an industry leader of Shlomo’s caliber join the Board,” said Frank Kung, Chairman of the Board of Sagent. “His extensive knowledge of the global generic pharmaceutical industry and broad strategic experience in helping companies successfully execute aggressive growth strategies will be invaluable to Sagent going forward. We look forward to benefiting from his contributions and advice as we pursue the next stage of our corporate evolution.”
“I have been impressed with Sagent’s unique business model, growth strategy and strong leadership team,” said Shlomo Yanai. “I look forward to working with the Company to build upon its success in the years ahead and help guide it to its next level of performance.”
Mr. Yanai, 63, served as President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. from 2007 until 2012. Under his leadership Teva grew revenue from $8.4 billion to $18.3 billion and increased earnings from $1.9 billion to $4.4 billion through a combination of organic and external growth programs. Prior to joining Teva, Mr. Yanai was President and CEO of Makhseshim Agan Industries from 2003 till 2006. Mr. Yanai began his career with the Israel Defense Forces, where he retired with the rank of Major General. He is currently the Chairman of the Board of the Cambrex Corporation, Chairman of the Board of Protalix Biotherapeutics, Vice Chairman of the Rothschild Caesarea Foundation and a Board member at Lumenis and Quinpario Acquisition Corp. 2. Mr. Yanai is a graduate of the Harvard Business School’s AMP program (2001), holds a Master’s degree (MPA) from the George Washington University in National Resource Administration (1990). His B.A. cum laude is in Political Science and Economics from Tel Aviv University (1983) and he is a graduate of the U.S. National Defense University- War College (1989).
About Sagent Pharmaceuticals
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
